Review

mscs imscs (ATCC)

ATCC is a verified supplier

ATCC manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ATCC mscs imscs

Substrate and BM‐MSC EV characterization. (a) Elastic moduli of substrates made with varying ratios of Sylgard 184 base to crosslinker reagents. All values expressed as mean ± SD ( n = 3). (b) Absorbance values indicating cell viability as determined by CCK8 assay over 5 days. All values expressed as mean ± SD ( n = 3). (c) Size distribution from nanoparticle tracking analysis of EVs isolated from <t>BM‐MSCs</t> seeded on Sylgard 184 PDMS substrates with differing base to crosslinker reagent ratios ( n = 3). (d) Representative Western blot of BM‐MSC EVs from each of the Sylgard 184 PDMS substrates and the corresponding cell lysates for EV‐positive markers ALIX, TSG101, and CD63 and cellular markers Calnexin and GAPDH (15 μg/lane). (e) Representative TEM images of BM‐MSC EVs from the softest Sylgard 184 PDMS substrates and collagen‐coated flasks. Statistical significance was determined by ANOVA; **p < 0.01, ***p < 0.001, and ****p < 0.0001.

Mscs Imscs, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 84 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mscs imscs/product/ATCC
Average 95 stars, based on 84 article reviews

mscs imscs - by Bioz Stars, 2026-03

95/100 stars

Images

1) Product Images from "Mesenchymal stem cell extracellular vesicle vascularization bioactivity and production yield are responsive to cell culture substrate stiffness"

Article Title: Mesenchymal stem cell extracellular vesicle vascularization bioactivity and production yield are responsive to cell culture substrate stiffness

Journal: Bioengineering & Translational Medicine

doi: 10.1002/btm2.10743

Figure Legend Snippet: Substrate and BM‐MSC EV characterization. (a) Elastic moduli of substrates made with varying ratios of Sylgard 184 base to crosslinker reagents. All values expressed as mean ± SD ( n = 3). (b) Absorbance values indicating cell viability as determined by CCK8 assay over 5 days. All values expressed as mean ± SD ( n = 3). (c) Size distribution from nanoparticle tracking analysis of EVs isolated from BM‐MSCs seeded on Sylgard 184 PDMS substrates with differing base to crosslinker reagent ratios ( n = 3). (d) Representative Western blot of BM‐MSC EVs from each of the Sylgard 184 PDMS substrates and the corresponding cell lysates for EV‐positive markers ALIX, TSG101, and CD63 and cellular markers Calnexin and GAPDH (15 μg/lane). (e) Representative TEM images of BM‐MSC EVs from the softest Sylgard 184 PDMS substrates and collagen‐coated flasks. Statistical significance was determined by ANOVA; **p < 0.01, ***p < 0.001, and ****p < 0.0001.

Techniques Used: CCK-8 Assay, Isolation, Western Blot

Substrate stiffness influences BM‐MSC EV production and bioactivity. (a) EV production as quantified by EVs per cell from BM‐MSCs seeded on Sylgard 184 PDMS substrates with different base‐to‐crosslinker ratios. EVs used for this data were from 1 day of collection and isolated and counted separately from the conditioned media from the other 2 days. After media collection, cells were trypsinized and counted ( n = 3). (b) After a scratch was induced, HUVECs were treated with BM‐MSC EVs from the different substrates or growth or basal media, and percent gap closure after 20 h was evaluated via microscopy ( n = 3). (c) HUVECs were resuspended in EV treatments or growth or basal endothelial media, seeded in Matrigel‐coated wells, and tube formation after 3–6 h was quantified by the number of loops that had formed ( n = 3). All values expressed as mean ± SD. All data are representative of at least three independent experiments ( n = 3). Statistical significance was determined by ANOVA; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

Figure Legend Snippet: Substrate stiffness influences BM‐MSC EV production and bioactivity. (a) EV production as quantified by EVs per cell from BM‐MSCs seeded on Sylgard 184 PDMS substrates with different base‐to‐crosslinker ratios. EVs used for this data were from 1 day of collection and isolated and counted separately from the conditioned media from the other 2 days. After media collection, cells were trypsinized and counted ( n = 3). (b) After a scratch was induced, HUVECs were treated with BM‐MSC EVs from the different substrates or growth or basal media, and percent gap closure after 20 h was evaluated via microscopy ( n = 3). (c) HUVECs were resuspended in EV treatments or growth or basal endothelial media, seeded in Matrigel‐coated wells, and tube formation after 3–6 h was quantified by the number of loops that had formed ( n = 3). All values expressed as mean ± SD. All data are representative of at least three independent experiments ( n = 3). Statistical significance was determined by ANOVA; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

Techniques Used: Isolation, Microscopy

Softer 184:527 PDMS substrates improve the angiogenic bioactivity of BM‐MSC EVs. (a) EV production quantified as EV per cell from BM‐MSCs seeded on each substrate made with different ratios of Sylgard 184 and Sylgard 527 ( n = 2). EVs used for this data were from 1 day of collection and isolated and counted separately from the conditioned media from the other 2 days. After media collection, cells were trypsinized and counted. (b) After a scratch was induced, HUVECs were treated with BM‐MSC EVs from the different substrates or growth or basal media, and percent gap closure after 20 h was evaluated via microscopy ( n = 3). (c) HUVECs were resuspended in the different EV treatments or growth or basal endothelial basal media, and tube formation after 3–6 h was quantified by the number of loops that had formed ( n = 3). All values expressed as mean ± SD. Statistical significance was determined by ANOVA; * p < 0.05, ** p < 0.01, and **** p < 0.0001.

Figure Legend Snippet: Softer 184:527 PDMS substrates improve the angiogenic bioactivity of BM‐MSC EVs. (a) EV production quantified as EV per cell from BM‐MSCs seeded on each substrate made with different ratios of Sylgard 184 and Sylgard 527 ( n = 2). EVs used for this data were from 1 day of collection and isolated and counted separately from the conditioned media from the other 2 days. After media collection, cells were trypsinized and counted. (b) After a scratch was induced, HUVECs were treated with BM‐MSC EVs from the different substrates or growth or basal media, and percent gap closure after 20 h was evaluated via microscopy ( n = 3). (c) HUVECs were resuspended in the different EV treatments or growth or basal endothelial basal media, and tube formation after 3–6 h was quantified by the number of loops that had formed ( n = 3). All values expressed as mean ± SD. Statistical significance was determined by ANOVA; * p < 0.05, ** p < 0.01, and **** p < 0.0001.

Techniques Used: Isolation, Microscopy

(a) EV production as quantified by EV per cell by EVs from iMSCs on different PDMS substrates. (b) EV size and concentration distribution from iMSCs cultured on different PDMS substrates as determined by nanoparticle tracking analysis. (c) iMSC proliferation/viability on PDMS substrates as measured by cell counting over 4 days. (d) Representative TEM images of F + C EVs and 527 EVs confirming morphology. (e) Western blot of EV markers CD63, ALIX, and TSG101, and EV‐negative marker, calnexin, on EVs from each PDMS substrate (12 μg/lane). (f) Western blot of MSC markers CD73, CD105, and CD90 and negative marker CD45 on iMSC lysate from each PDMS substrate. THP1 cell lysate was used as a positive control for CD45. (5 μg/lane). All values expressed as mean ± SD. Statistical significance was determined by ANOVA; ** p < 0.01.

Figure Legend Snippet: (a) EV production as quantified by EV per cell by EVs from iMSCs on different PDMS substrates. (b) EV size and concentration distribution from iMSCs cultured on different PDMS substrates as determined by nanoparticle tracking analysis. (c) iMSC proliferation/viability on PDMS substrates as measured by cell counting over 4 days. (d) Representative TEM images of F + C EVs and 527 EVs confirming morphology. (e) Western blot of EV markers CD63, ALIX, and TSG101, and EV‐negative marker, calnexin, on EVs from each PDMS substrate (12 μg/lane). (f) Western blot of MSC markers CD73, CD105, and CD90 and negative marker CD45 on iMSC lysate from each PDMS substrate. THP1 cell lysate was used as a positive control for CD45. (5 μg/lane). All values expressed as mean ± SD. Statistical significance was determined by ANOVA; ** p < 0.01.

Techniques Used: Concentration Assay, Cell Culture, Cell Counting, Western Blot, Marker, Positive Control

Substrate stiffness affects the pro‐angiogenic effect of iMSC EVs comparably to BM‐MSC EVs. (a) EVs isolated from iMSCs on different 184:527 PDMS substrates were used to treat HUVECs after a scratch had been induced, and percent gap closure after 20 h was evaluated via microscopy. (b) HUVECs were resuspended with the same EV groups and seeded, and tube formation after 3–6 h was quantified by the number of loops that had formed. All values expressed as mean ± SD. All data are representative of at least three independent experiments ( n = 3). Statistical significance was determined by ANOVA; * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

Figure Legend Snippet: Substrate stiffness affects the pro‐angiogenic effect of iMSC EVs comparably to BM‐MSC EVs. (a) EVs isolated from iMSCs on different 184:527 PDMS substrates were used to treat HUVECs after a scratch had been induced, and percent gap closure after 20 h was evaluated via microscopy. (b) HUVECs were resuspended with the same EV groups and seeded, and tube formation after 3–6 h was quantified by the number of loops that had formed. All values expressed as mean ± SD. All data are representative of at least three independent experiments ( n = 3). Statistical significance was determined by ANOVA; * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

Techniques Used: Isolation, Microscopy

MiRNA qPCR array data of differentially expressed MSC EV‐associated miRNAs in flask vs. soft substrate‐generated EVs. (a) Fold change of miRNAs within EVs from iMSCs seeded on 527 PDMS normalized to the miRNA levels within EVs from iMSCs seeded on collagen‐coated flasks. (b) The same data represented as the log2 of the fold change, again normalized to the miRNA levels within EVs from iMSCs seeded on collagen‐coated flasks. All data are representative of at least three independent experiments ( n = 3).

Figure Legend Snippet: MiRNA qPCR array data of differentially expressed MSC EV‐associated miRNAs in flask vs. soft substrate‐generated EVs. (a) Fold change of miRNAs within EVs from iMSCs seeded on 527 PDMS normalized to the miRNA levels within EVs from iMSCs seeded on collagen‐coated flasks. (b) The same data represented as the log2 of the fold change, again normalized to the miRNA levels within EVs from iMSCs seeded on collagen‐coated flasks. All data are representative of at least three independent experiments ( n = 3).

Techniques Used: Generated

Image Search Results

Journal: Bioengineering & Translational Medicine

Article Title: Mesenchymal stem cell extracellular vesicle vascularization bioactivity and production yield are responsive to cell culture substrate stiffness

doi: 10.1002/btm2.10743

Figure Lengend Snippet: Substrate and BM‐MSC EV characterization. (a) Elastic moduli of substrates made with varying ratios of Sylgard 184 base to crosslinker reagents. All values expressed as mean ± SD ( n = 3). (b) Absorbance values indicating cell viability as determined by CCK8 assay over 5 days. All values expressed as mean ± SD ( n = 3). (c) Size distribution from nanoparticle tracking analysis of EVs isolated from BM‐MSCs seeded on Sylgard 184 PDMS substrates with differing base to crosslinker reagent ratios ( n = 3). (d) Representative Western blot of BM‐MSC EVs from each of the Sylgard 184 PDMS substrates and the corresponding cell lysates for EV‐positive markers ALIX, TSG101, and CD63 and cellular markers Calnexin and GAPDH (15 μg/lane). (e) Representative TEM images of BM‐MSC EVs from the softest Sylgard 184 PDMS substrates and collagen‐coated flasks. Statistical significance was determined by ANOVA; **p < 0.01, ***p < 0.001, and ****p < 0.0001.

Article Snippet: Human induced pluripotent stem cell‐derived MSCs (iMSCs) were also purchased from ATCC (ACS‐7010).

Techniques: CCK-8 Assay, Isolation, Western Blot

Journal: Bioengineering & Translational Medicine

Article Title: Mesenchymal stem cell extracellular vesicle vascularization bioactivity and production yield are responsive to cell culture substrate stiffness

doi: 10.1002/btm2.10743

Figure Lengend Snippet: Substrate stiffness influences BM‐MSC EV production and bioactivity. (a) EV production as quantified by EVs per cell from BM‐MSCs seeded on Sylgard 184 PDMS substrates with different base‐to‐crosslinker ratios. EVs used for this data were from 1 day of collection and isolated and counted separately from the conditioned media from the other 2 days. After media collection, cells were trypsinized and counted ( n = 3). (b) After a scratch was induced, HUVECs were treated with BM‐MSC EVs from the different substrates or growth or basal media, and percent gap closure after 20 h was evaluated via microscopy ( n = 3). (c) HUVECs were resuspended in EV treatments or growth or basal endothelial media, seeded in Matrigel‐coated wells, and tube formation after 3–6 h was quantified by the number of loops that had formed ( n = 3). All values expressed as mean ± SD. All data are representative of at least three independent experiments ( n = 3). Statistical significance was determined by ANOVA; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

Article Snippet: Human induced pluripotent stem cell‐derived MSCs (iMSCs) were also purchased from ATCC (ACS‐7010).

Techniques: Isolation, Microscopy

Journal: Bioengineering & Translational Medicine

Article Title: Mesenchymal stem cell extracellular vesicle vascularization bioactivity and production yield are responsive to cell culture substrate stiffness

doi: 10.1002/btm2.10743

Figure Lengend Snippet: Softer 184:527 PDMS substrates improve the angiogenic bioactivity of BM‐MSC EVs. (a) EV production quantified as EV per cell from BM‐MSCs seeded on each substrate made with different ratios of Sylgard 184 and Sylgard 527 ( n = 2). EVs used for this data were from 1 day of collection and isolated and counted separately from the conditioned media from the other 2 days. After media collection, cells were trypsinized and counted. (b) After a scratch was induced, HUVECs were treated with BM‐MSC EVs from the different substrates or growth or basal media, and percent gap closure after 20 h was evaluated via microscopy ( n = 3). (c) HUVECs were resuspended in the different EV treatments or growth or basal endothelial basal media, and tube formation after 3–6 h was quantified by the number of loops that had formed ( n = 3). All values expressed as mean ± SD. Statistical significance was determined by ANOVA; * p < 0.05, ** p < 0.01, and **** p < 0.0001.

Article Snippet: Human induced pluripotent stem cell‐derived MSCs (iMSCs) were also purchased from ATCC (ACS‐7010).

Techniques: Isolation, Microscopy

Journal: Bioengineering & Translational Medicine

Article Title: Mesenchymal stem cell extracellular vesicle vascularization bioactivity and production yield are responsive to cell culture substrate stiffness

doi: 10.1002/btm2.10743

Figure Lengend Snippet: (a) EV production as quantified by EV per cell by EVs from iMSCs on different PDMS substrates. (b) EV size and concentration distribution from iMSCs cultured on different PDMS substrates as determined by nanoparticle tracking analysis. (c) iMSC proliferation/viability on PDMS substrates as measured by cell counting over 4 days. (d) Representative TEM images of F + C EVs and 527 EVs confirming morphology. (e) Western blot of EV markers CD63, ALIX, and TSG101, and EV‐negative marker, calnexin, on EVs from each PDMS substrate (12 μg/lane). (f) Western blot of MSC markers CD73, CD105, and CD90 and negative marker CD45 on iMSC lysate from each PDMS substrate. THP1 cell lysate was used as a positive control for CD45. (5 μg/lane). All values expressed as mean ± SD. Statistical significance was determined by ANOVA; ** p < 0.01.

Article Snippet: Human induced pluripotent stem cell‐derived MSCs (iMSCs) were also purchased from ATCC (ACS‐7010).

Techniques: Concentration Assay, Cell Culture, Cell Counting, Western Blot, Marker, Positive Control

Journal: Bioengineering & Translational Medicine

Article Title: Mesenchymal stem cell extracellular vesicle vascularization bioactivity and production yield are responsive to cell culture substrate stiffness

doi: 10.1002/btm2.10743

Figure Lengend Snippet: Substrate stiffness affects the pro‐angiogenic effect of iMSC EVs comparably to BM‐MSC EVs. (a) EVs isolated from iMSCs on different 184:527 PDMS substrates were used to treat HUVECs after a scratch had been induced, and percent gap closure after 20 h was evaluated via microscopy. (b) HUVECs were resuspended with the same EV groups and seeded, and tube formation after 3–6 h was quantified by the number of loops that had formed. All values expressed as mean ± SD. All data are representative of at least three independent experiments ( n = 3). Statistical significance was determined by ANOVA; * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

Article Snippet: Human induced pluripotent stem cell‐derived MSCs (iMSCs) were also purchased from ATCC (ACS‐7010).

Techniques: Isolation, Microscopy

Journal: Bioengineering & Translational Medicine

Article Title: Mesenchymal stem cell extracellular vesicle vascularization bioactivity and production yield are responsive to cell culture substrate stiffness

doi: 10.1002/btm2.10743

Figure Lengend Snippet: MiRNA qPCR array data of differentially expressed MSC EV‐associated miRNAs in flask vs. soft substrate‐generated EVs. (a) Fold change of miRNAs within EVs from iMSCs seeded on 527 PDMS normalized to the miRNA levels within EVs from iMSCs seeded on collagen‐coated flasks. (b) The same data represented as the log2 of the fold change, again normalized to the miRNA levels within EVs from iMSCs seeded on collagen‐coated flasks. All data are representative of at least three independent experiments ( n = 3).

Article Snippet: Human induced pluripotent stem cell‐derived MSCs (iMSCs) were also purchased from ATCC (ACS‐7010).

Techniques: Generated

Review

Structured Review

Images

1) Product Images from "Mesenchymal stem cell extracellular vesicle vascularization bioactivity and production yield are responsive to cell culture substrate stiffness"

Similar Products

Image Search Results